Uncertain Times: New Lockdowns, Ukraine Challenge Chinese Pharma
Executive Summary
As residents of China's largest city brace for a possible prolonged lockdown, the gathering COVID-19 outbreak is set to cause some pharma disruption in the country, while broader geopolitical factors including Ukraine are hindering the industry's global ambitions.
You may also be interested in...
Russia Sanctions, China Lockdown To Pinch Globally With Higher Freight, API Costs
With the Shanghai lockdown extended, Russian vessels blacklisted and oil prices fluctuating, global freight rates are expected to increase further. Apart from a direct hit, pharma manufacturers will also feel the ripple effect as prices of raw materials like APIs increase. Scrip spoke to Indian industry to gauge the impact.
China Planning To Ban Gene Editing Technology Exports
Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.
Behind A Rekindled Dream And China Biotech’s New Reality
The latest mega deals aimed at bringing Chinese innovation to the US have rekindled go-global hopes for a sector badly needing some cheer. But some investors say out-licensing may be the best route and that Chinese biotech must scale back its do-all mentality and focus on what it does best amid a new reality.